Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]S. C. Chauhan, M. Jaggi, M. C. Bell, M. Verma and D. Kumar: Epidemiology of Human Papilloma Virus (HPV) in Cervical Mucosa. Methods Mol Biol, 471, 439-56 (2009)

  • [2]G. Peng, W. Dan, W. Jun, Y. Junjun, R. Tong, Z. Baoli and X. Yang: Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing. Tumour Biol, 36(5), 3309-17 (2015)

  • [3]N. A. Howlader N, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds): Cancer Statistics Review, 1975-2013. SEER data submission (November 2015)

  • [4]E. M. Burd: Human papillomavirus and cervical cancer. Clin Microbiol Rev, 16(1), 1-17 (2003)

  • [5]S. Hariri, N. M. Bennett, L. M. Niccolai, S. Schafer, I. U. Park, K. C. Bloch, E. R. Unger, E. Whitney, P. Julian, M. W. Scahill, N. Abdullah, D. Levine, M. L. Johnson, M. Steinau, L. E. Markowitz and H.-I. W. Group: Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine, 33(13), 1608-13 (2015)

  • [6]G. Y. Ho, R. Bierman, L. Beardsley, C. J. Chang and R. D. Burk: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med, 338(7), 423-8 (1998)

  • [7].S. Hariri, E. R. Unger, S. Schafer, L. M. Niccolai, I. U. Park, K. C. Bloch, N. M. Bennett, M. Steinau, M. L. Johnson, L. E. Markowitz and H.-I. W. Group: HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. Cancer Epidemiol Biomarkers Prev, 24(2), 393-9 (2015)

  • [8]H. M. Jackson: Letter: The Appalachian Regional Commission. JAMA, 234(12), 1221 (1975)

  • [9]S. L. Wilson, C. Kratzke and J. Hoxmeier: Predictors of access to healthcare: what matters to rural Appalachians? Glob J Health Sci, 4(6), 23-35 (2012)

  • [10]P. E. Castle, A. Rausa, T. Walls, P. E. Gravitt, E. E. Partridge, V. Olivo, S. Niwa, K. G. Morrissey, L. Tucker, H. Katki and I. Scarinci: Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med, 52(6), 452-5 (2011)

  • [11]E. Johannsen and P. F. Lambert: Epigenetics of human papillomaviruses. Virology, 445(1-2), 205-12 (2013)

  • [12]C. P. Delury, E. K. Marsh, C. D. James, S. S. Boon, L. Banks, G. L. Knight and S. Roberts: The role of protein kinase A regulation of the E6 PDZ-binding domain during the differentiation-dependent life cycle of human papillomavirus type 18. J Virol, 87(17), 9463-72 (2013)

  • [13]M. Perez, S. E. Findley, M. Mejia and J. Martinez: The impact of community health worker training and programs in NYC. J Health Care Poor Underserved, 17(1 Suppl), 26-43 (2006)

  • [14]K. M. Kelly, A. K. Ferketich, M. T. Ruffin Iv, C. Tatum and E. D. Paskett: Perceived risk of cervical cancer in Appalachian women. Am J Health Behav, 36(6), 849-59 (2012)

  • [15]L. S. Downs, J. S. Smith, I. Scarinci, L. Flowers and G. Parham: The disparity of cervical cancer in diverse populations. Gynecol Oncol, 109(2 Suppl), S22-30 (2008)

  • [16]K. D. Blake, A. J. Ottenbacher, L. J. Finney Rutten, M. A. Grady, S. C. Kobrin, R. M. Jacobson and B. W. Hesse: Predictors of human papillomavirus awareness and knowledge in 2013: gaps and opportunities for targeted communication strategies. Am J Prev Med, 48(4), 402-10 (2015)

  • [17]R. Shell and F. Tudiver: Barriers to cancer screening by rural Appalachian primary care providers. J Rural Health, 20(4), 368-73 (2004)

  • [18]P. L. Reiter, M. L. Katz, A. K. Ferketich, M. T. t. Ruffin and E. D. Paskett: Measuring cervical cancer risk: development and validation of the CARE Risky Sexual Behavior Index. Cancer Causes Control, 20(10), 1865-71 (2009)

  • [19]E. D. Paskett, J. M. McLaughlin, A. M. Lehman, M. L. Katz, C. M. Tatum and J. M. Oliveri: Evaluating the efficacy of lay health advisors for increasing risk-appropriate Pap test screening: a randomized controlled trial among Ohio Appalachian women. Cancer Epidemiol Biomarkers Prev, 20(5), 835-43 (2011)

  • [20]S. D. Singh, S. J. Henley and A. B. Ryerson: Summary of Notifiable Noninfectious Conditions and Disease Outbreaks: Surveillance for Cancer Incidence and Mortality - United States, 2011. MMWR Morb Mortal Wkly Rep, 62(54), 11-51 (2015)

  • [21]D. C. Schmidt-Grimminger, M. C. Bell, C. J. Muller, D. M. Maher, S. C. Chauhan and D. S. Buchwald: HPV infection among rural American Indian women and urban white women in South Dakota: an HPV prevalence study. BMC Infect Dis, 11, 252 (2011)

  • [22]M. C. Bell, D. Schmidt-Grimminger, C. Jacobsen, S. C. Chauhan, D. M. Maher and D. S. Buchwald: Risk factors for HPV infection among American Indian and white women in the Northern Plains. Gynecol Oncol, 121(3), 532-6 (2011)

  • [23]J. Duvall and D. Buchwald: Human papillomavirus vaccine policies among american Indian tribes in Washington State. J Pediatr Adolesc Gynecol, 25(2), 131-5 (2012)

  • [24]A. S. Ramirez, L. J. Rutten, A. Oh, B. L. Vengoechea, R. P. Moser, R. C. Vanderpool and B. W. Hesse: Perceptions of cancer controllability and cancer risk knowledge: the moderating role of race, ethnicity, and acculturation. J Cancer Educ, 28(2), 254-61 (2013)

  • [25]P. L. Reiter, M. L. Katz, M. T. Ruffin, E. M. Hade, C. R. DeGraffenreid, D. A. Patel, E. D. Paskett and E. R. Unger: HPV prevalence among women from Appalachia: results from the CARE project. PLoS One, 8(8), e74276 (2013)

  • [26]R. C. Vanderpool, E. V. Dressler, L. R. Stradtman and R. A. Crosby: Fatalistic beliefs and completion of the HPV vaccination series among a sample of young Appalachian Kentucky women. J Rural Health, 31(2), 199-205 (2015)

  • [27]P. L. Reiter, J. L. Fisher, A. G. Hudson, T. C. Tucker, J. J. Plascak and E. D. Paskett: Assessing the burden of HPV-related cancers in Appalachia. Hum Vaccin Immunother, 9(1), 90-6 (2013)

  • [28]C. E. Banister, A. R. Messersmith, B. Cai, L. B. Spiryda, S. H. Glover, L. Pirisi and K. E. Creek: Disparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age. J Infect Dis, 211(1), 100-8 (2015)

  • [29]T. T. Prata, C. M. Bonin, A. M. Ferreira, C. T. Padovani, C. E. Fernandes, A. P. Machado and I. A. Tozetti: Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology, 146(1), 113-21 (2015)

  • [30]L. Y. Hwang, M. E. Scott, Y. Ma and A. B. Moscicki: Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol, 88(1), 66-71 (2011)

  • [31]T. J. Kemp, A. Hildesheim, A. Garcia-Pineres, M. C. Williams, G. M. Shearer, A. C. Rodriguez, M. Schiffman, R. Burk, E. Freer, J. Bonilla, R. Herrero and L. A. Pinto: Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol Biomarkers Prev, 19(8), 1954-9 (2010)

  • [32]V. A. Govan, D. Constant, M. Hoffman and A. L. Williamson: The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer, 6, 24 (2006)

  • [33]A. Deshpande, J. P. Nolan, P. S. White, Y. E. Valdez, W. C. Hunt, C. L. Peyton and C. M. Wheeler: TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis, 191(6), 969-76 (2005)

  • [34]M. I. Rosa, M. V. Moraes, F. Vuolo, F. Petronilho, M. C. Bozzetti, L. R. Medeiros, C. N. Igansi, F. R. Silva, F. Dal-Pizzol and D. D. Rosa: Association of interleukin-6 in women with persistence of DNA-HPV: a nested case-control study. Arch Gynecol Obstet, 285(1), 143-8 (2012)

  • [35]M. H. Hibma: The immune response to papillomavirus during infection persistence and regression. Open Virol J, 6, 241-8 (2012)

  • [36]P. L. Reiter, M. L. Katz and E. D. Paskett: HPV vaccination among adolescent females from Appalachia: implications for cervical cancer disparities. Cancer Epidemiol Biomarkers Prev, 21(12), 2220-30 (2012)

  • [37]K. Torres-Poveda, A. I. Burguete-Garcia, M. Cruz, G. A. Martinez-Nava, M. Bahena-Roman, E. Ortiz-Flores, A. Ramirez-Gonzalez, G. Lopez-Estrada, K. Delgado-Romero and V. Madrid-Marina: The SNP at -592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development. Infect Agent Cancer, 7(1), 32 (2012)

  • [38]D. A. Patel, L. S. Rozek, J. A. Colacino, A. Van Zomeren-Dohm, M. T. Ruffin, E. R. Unger, D. C. Dolinoy, D. C. Swan, J. Onyekwuluje, C. R. DeGraffinreid and E. D. Paskett: Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. J Virol Methods, 184(1-2), 84-92 (2012)

  • [39]D. Gustinucci, P. Giorgi Rossi, E. Cesarini, M. Broccolini, S. Bulletti, A. Carlani, V. D'Angelo, R. D'Amico M, E. Di Dato, P. Galeazzi, M. Malaspina, N. Martinelli, N. Spita, B. Tintori, M. D. Giaimo and B. Passamonti: Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the Management of Human Papillomavirus (HPV)-Positive Women in Cervical Cancer Screening. Am J Clin Pathol, 145(1), 35-45 (2016)

  • [40]M. Filippova, V. A. Filippov, M. Kagoda, T. Garnett, N. Fodor and P. J. Duerksen-Hughes: Complexes of human papillomavirus type 16 E6 proteins form pseudo-death-inducing signaling complex structures during tumor necrosis factor-mediated apoptosis. J Virol, 83(1), 210-27 (2009)

  • [41]A. M. Narasimha, M. Kaulich, G. S. Shapiro, Y. J. Choi, P. Sicinski and S. F. Dowdy: Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife, 3 (2014)

  • [42]J. Wang, Q. Wang, H. Liu, N. Shao, B. Tan, G. Zhang, K. Wang, Y. Jia, W. Ma, N. Wang and Y. Cheng: The association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis, 27(6), 779-88 (2012)

  • [43]K. Gocze, K. Gombos, K. Kovacs, K. Juhasz, P. Gocze and I. Kiss: MicroRNA expressions in HPV-induced cervical dysplasia and cancer. Anticancer Res, 35(1), 523-30 (2015)

  • [44]V. H. Bermudez-Morales, L. X. Gutierrez, J. M. Alcocer-Gonzalez, A. Burguete and V. Madrid-Marina: Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest, 26(10), 1037-43 (2008)

  • [45]L. Wang, Q. Wang, H. L. Li and L. Y. Han: Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma--relationship with prognosis. Asian Pac J Cancer Prev, 14(3), 2113-8 (2013)

  • [46]G. Reshmi, R. Surya, V. T. Jissa, P. S. Babu, N. R. Preethi, W. S. Santhi, P. G. Jayaprakash and M. R. Pillai: C-T variant in a miRNA target site of BCL2 is associated with increased risk of human papilloma virus related cervical cancer--an in silico approach. Genomics, 98(3), 189-93 (2011)

  • [47]D. P. Malinowski: Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques, Suppl, 17-23 (2005)

  • [48]S. J. Lim, H. J. Kim, J. Y. Kim, K. Park and C. M. Lee: Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol, 26(3), 229-34 (2007)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2017Review

Disparity in rates of HPV infection and cervical cancer in underserved US populations

Asok Ranjan Karuri 1, Vivek Kumar Kashyap 1, Murali Mohan Yallapu 1, Nadeem Zafar 2, Satish K. Kedia 3, Meena Jaggi 1, Subhash C. Chauhan 1,*
Affiliations
Article Info

1 Department of Pharmaceutical Sciences and Cancer Research Center, University of Tennessee Health Science Center, Memphis, Tennessee, USA, 38163

2 Department of Pathology, University of Tennessee Health Science Center, Memphis, Tennessee, USA, 38163

3 Division of Social and Behavioral Sciences, School of Public Health, University of Memphis, Memphis, TN, 38152

*Author to whom correspondence should be addressed.

 

Abstract

There is a higher rate of HPV infection and cervical cancer incidence and mortality in underserved US population who reside in Appalachian mountain region compared to Northern Plains. Social and behavioral factors such as smoking and alcohol consumption are for such a high incidence. However, by and large, the reasons for these discrepancies lie in the reluctance of the underserved population to adopt preventive measures such as prophylactic Human papilloma virus (HPV) vaccines and Pap smear screening that have significantly reduced the incidence and mortality rate of cervical cancer in Caucasian women. Thus, it is clear that drastic change in social behavior and implementation of preventive measures is required to effectively reduce the incidence and mortality from cervical cancer in this underserved population.

Keywords

  • PV
  • HPV genotype
  • Cervical Cancer
  • Health Disparity
  • Vaccination
  • Appalachian women
  • American Indian
  • African American
  • Review

References